Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction (PH-HFpEF)Expansion of U.S. Intellectual Property Covering the Use of Levosimendan for the Treatment of PH-HFpEF and for Use in Combination with Other Cardiovascular Therapies The Company Secured Global Commercial Rights to Levosimendan for the Treatment of PH-HFpEFThe Company will host a KOL Event, “LEVEL Setting: Th
CHAPEL HILL, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will participate in the 36th Annual Roth Conference in Dana Point, California, from March 17-19, 2024. Tenax’s CEO, Chris Giordano, will provide an update on the company and the ongoin
Dr. Sanjiv Shah, a renowned, global expert in the treatment of HFpEF and PH-HFpEF, will present data highlighting the use of levosimendan for the treatment of pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) Presentation will occur at Technology and Heart Failure Therapeutics (THT-2024) – in Boston, MA, on March 6, 2024 THT 2024 is an international conference of leading Heart Failure experts focused on innovations in Heart Failure treatment CHAPEL HILL, N.C
Amendment to existing exclusive license agreement with Orion Corporation expands Tenax’s territory rights from North America, to the entire worldExpanded rights position Tenax to engage potential global strategic pharmaceutical partners Improved net sales royalty rate structure, now ranging from high single-digit to low-teen percentages. Lowered maximum cost of goodsModified milestone provisions, including additional payment for regulatory approval in Japan, reflect multi-billion dollar global P
By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT What’s New? On the heels of a share balance consolidation, Tenax Therapeutics, Inc. (NASDAQ:TENX) began February with a burst of activity. It announced a notice of allowance from the USPTO, the enrollment of its first patient in the LEVEL trial and pricing of $9 million in funds to support clinical efforts. Read on for the
CHAPEL HILL, N.C., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today the pricing of a public offering of (i) 1,600,000 shares of its common stock (or pre-funded warrants in lieu thereof) and (ii) warrants to purchase up to 3,200,000 shares of its common stock (the “Common Warran
Over 40 sites (U.S. and Canada) have agreed to participate in the LEVEL study LEVEL is a randomized, controlled Phase 3 trial of 152 patients, and will recruit patients primarily from leading research centers with large PH-HFpEF populations Tenax forecasts topline LEVEL data will be available second half of 2025 CHAPEL HILL, N.C., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing pr
Once granted, this patent will: provide U.S. intellectual property (IP) protection until December 2040, and may qualify for additional U.S. patent term extension (PTE) beyond 2040broaden IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEFexpressly provide IP protection for levosimendan at all therapeutic doses for use in PH-HFpEF expressly provide IP protection for levosimendan in combination with various cardiov
Tenax Therapeutics, Inc. ( NASDAQ:TENX ) is possibly approaching a major achievement in its business, so we would like...
CHAPEL HILL, N.C., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that it will be executing a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-80. The reverse stock split will become effective at 5:00 pm Eastern Time on January 2, 2024. The Co